{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:46Z","timestamp":1791357286025,"version":"4.3.1"},"reference-count":143,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","jprasurg.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Plastic, Reconstructive & Aesthetic Surgery"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.bjps.2016.01.034","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T15:26:12Z","timestamp":1465313172000},"page":"e119-e153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["UK guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in adults 2016"],"prefix":"10.1016","volume":"69","author":[{"given":"D.","family":"Creamer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dziewulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.S.","family":"Exton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.G.","family":"Dart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Setterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.B.","family":"Bunker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Ardern-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.T.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.E.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Philippidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vercueil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.V.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.F.","family":"Mohd Mustapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjps.2016.01.034_bib1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2133.2008.09026.x","article-title":"Writing a British Association of Dermatologists clinical guideline: an update on the process and guidance for authors","volume":"160","author":"Bell","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib2","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.bjps.2016.01.034_bib3","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjps.2016.01.034_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981\u20131985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990\u20131992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.bjps.2016.01.034_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0190-9622(90)70333-D","article-title":"Toxic epidermal necrolysis (Lyell syndrome)","volume":"23","author":"Roujeau","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2332\/allergolint.55.27","article-title":"Immune mechanisms in drug allergy","volume":"55","author":"Roujeau","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.bjps.2016.01.034_bib9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bjps.2016.01.034_bib10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jaad.2011.09.029","article-title":"Toxic epidermal necrolysis: review of pathogenesis and management","volume":"66","author":"Downey","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.bjps.2016.01.034_bib13","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S1081-1206(10)60789-2","article-title":"Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"97","author":"Khalili","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.bjps.2016.01.034_bib14","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.bjps.2016.01.034_bib15","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes","volume":"131","author":"Assier","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib19","article-title":"Mycoplasma pneumoniae-associated mucositis - case report and systematic review of literature","author":"Vujic","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.bjps.2016.01.034_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1996.tb03598.x","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bjps.2016.01.034_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib23","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjps.2016.01.034_bib24","first-page":"2234","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective","volume":"30","author":"Mockenhaupt","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/03009748709102191","article-title":"Clinical aspects of skin reactions to NSAIDs","volume":"65","author":"Roujeau","year":"1987","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.bjps.2016.01.034_bib26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/archderm.1987.01660330077013","article-title":"The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome)","volume":"123","author":"Guillaume","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib27","first-page":"95","article-title":"Cutaneous adverse drug reactions: clinical pattern and causative agents\u2013a 6 year series from Chandigarh, India","volume":"47","author":"Sharma","year":"2001","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.bjps.2016.01.034_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A 10-year experience with toxic epidermal necrolysis","volume":"21","author":"Schulz","year":"2000","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2016.01.034_bib30","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/00006534-200209010-00008","article-title":"Outcome of patients with toxic epidermal necrolysis syndrome revisited","volume":"110","author":"Ducic","year":"2002","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.bjps.2016.01.034_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Gu\u00e9gan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib33","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archderm.140.7.890","article-title":"Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States","volume":"140","author":"Trent","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/00015550510038232","article-title":"Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients","volume":"85","author":"Kim","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.bjps.2016.01.034_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/BCR.0b013e31815f3865","article-title":"SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center","volume":"29","author":"Cartotto","year":"2008","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.bjps.2016.01.034_bib36","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2230.2010.03826.x","article-title":"Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre","volume":"35","author":"Rajaratnam","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ajo.2010.04.026","article-title":"Ophthalmic manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN","volume":"150","author":"Morales","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.bjps.2016.01.034_bib38","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809020-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.bjps.2016.01.034_bib39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2016.01.034_bib40","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.burns.2014.02.006","article-title":"A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres","volume":"40","author":"Mahar","year":"2014","journal-title":"Burns"},{"key":"10.1016\/j.bjps.2016.01.034_bib41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00005373-198108001-00024","article-title":"Mediators of metabolism","volume":"21","author":"Herndon","year":"1981","journal-title":"J Trauma"},{"key":"10.1016\/j.bjps.2016.01.034_bib42","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(04)16360-5","article-title":"Support of the metabolic response to burn injury","volume":"363","author":"Herndon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bjps.2016.01.034_bib43","first-page":"10","article-title":"How far would you go to save someone's skin?","volume":"8","author":"Brown","year":"2009","journal-title":"Dermatol Nurs"},{"key":"10.1016\/j.bjps.2016.01.034_bib44","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bjps.2014.04.003","article-title":"Toxic epidermal necrolysis (TEN): the Chelsea and Westminster Hospital wound management algorithm","volume":"67","author":"Abela","year":"2014","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.bjps.2016.01.034_bib45","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PRS.0b013e3181773d5d","article-title":"Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach","volume":"122","author":"Dorafshar","year":"2008","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.bjps.2016.01.034_bib46","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.burns.2006.08.014","article-title":"Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis","volume":"33","author":"Stella","year":"2007","journal-title":"Burns"},{"key":"10.1016\/j.bjps.2016.01.034_bib47","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.burns.2008.12.011","article-title":"Accurate debridement of toxic epidermal necrolysis using versajet","volume":"36","author":"Dillon","year":"2010","journal-title":"Burns"},{"key":"10.1016\/j.bjps.2016.01.034_bib48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","article-title":"Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures","volume":"89","author":"de Prost","year":"2010","journal-title":"Medicine"},{"key":"10.1016\/j.bjps.2016.01.034_bib49","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bjps.2006.09.003","article-title":"Resuscitation of thermal injuries in the United Kingdom and Ireland","volume":"60","author":"Baker","year":"2007","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.bjps.2016.01.034_bib50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/BCR.0b013e3181cb8cb8","article-title":"What are the fluid requirements in toxic epidermal necrolysis?","volume":"31","author":"Shiga","year":"2010","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.bjps.2016.01.034_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/011542659701200281","article-title":"Nutrition requirements in patients with toxic epidermal necrolysis","volume":"12","author":"Coss-Bu","year":"1997","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.bjps.2016.01.034_bib52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00004630-200101000-00022","article-title":"A 10-year experience with toxic epidermal necrolysis","volume":"22","author":"Hansbrough","year":"2001","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2016.01.034_bib53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/011542659100600118","article-title":"Toxic epidermal necrolysis","volume":"6","author":"Lacy","year":"1991","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.bjps.2016.01.034_bib54","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clnu.2006.01.021","article-title":"ESPEN guidelines on enteral nutrition: intensive care","volume":"25","author":"Kreymann","year":"2006","journal-title":"Clin Nutr"},{"key":"10.1016\/j.bjps.2016.01.034_bib55","series-title":"Cancer pain relief, with a guide to opioid availability","author":"World Health Organization","year":"1996"},{"key":"10.1016\/j.bjps.2016.01.034_bib56","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.annder.2011.05.029","article-title":"Pain management in Stevens-Johnson syndrome, toxic epidermal necrolysis and other blistering diseases","volume":"138","author":"Valeyrie-Allanore","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.bjps.2016.01.034_bib57","first-page":"11","article-title":"Prevention and treatment of stress ulcers in critically ill patients","volume":"14","author":"Yang","year":"2003","journal-title":"Semin Gastrointest Dis"},{"key":"10.1016\/j.bjps.2016.01.034_bib58","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2133.2009.09585.x","article-title":"Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN protocol","volume":"162","author":"de Sica-Chapman","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib59","first-page":"157","article-title":"Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"145","author":"Gueudry","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib60","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","article-title":"Analysis of the acute ophthalmic manifestations of the erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysis disease spectrum","volume":"102","author":"Power","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bjps.2016.01.034_bib61","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1398-9995.2006.01295.x","article-title":"Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series","volume":"62","author":"Yip","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.bjps.2016.01.034_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2015.05.002","article-title":"Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis","author":"Sotozono","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.bjps.2016.01.034_bib63","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ophtha.2014.08.013","article-title":"The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome","volume":"122","author":"Kim","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bjps.2016.01.034_bib64","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1007\/s00134-004-2203-y","article-title":"A randomised controlled study of the efficacy of hypromellose and Lacri-Lube combination versus polyethylene\/cling wrap to prevent corneal epithelial breakdown in the semiconscious intensive care patient","volume":"30","author":"Koroloff","year":"2004","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.bjps.2016.01.034_bib65","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1097\/CCM.0b013e31818f0ee7","article-title":"Eye care in the intensive care unit: narrative review and meta-analysis","volume":"36","author":"Rosenberg","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.bjps.2016.01.034_bib66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ophtha.2008.12.048","article-title":"Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications","volume":"116","author":"Sotozono","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bjps.2016.01.034_bib67","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajo.2008.12.040","article-title":"Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset","volume":"147","author":"Araki","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.bjps.2016.01.034_bib68","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.eye.6701653","article-title":"High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits","volume":"19","author":"Yip","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.bjps.2016.01.034_bib69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0161-6420(01)00900-9","article-title":"Amniotic membrane in the surgical management of acute toxic epidermal necrolysis","volume":"109","author":"John","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bjps.2016.01.034_bib70","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.ophtha.2011.01.046","article-title":"Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases","volume":"118","author":"Gregory","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bjps.2016.01.034_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2009.08.040","article-title":"Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids","volume":"149","author":"Shammas","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.bjps.2016.01.034_bib72","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ophtha.2005.09.001","article-title":"Amniotic membrane transplantation in acute phase of toxic epidermal necrolysis with severe corneal involvement","volume":"113","author":"Kobayashi","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bjps.2016.01.034_bib73","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.survophthal.2009.03.004","article-title":"Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Shay","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.bjps.2016.01.034_bib74","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/ICO.0b013e318243fee3","article-title":"\u201cTriple-TEN\u201d in the treatment of acute ocular complications from toxic epidermal necrolysis","volume":"32","author":"Tomlins","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.bjps.2016.01.034_bib75","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1097\/ICL.0b013e318255124f","article-title":"Placement of ProKera in the management of ocular manifestations of acute Stevens-Johnson syndrome in an outpatient","volume":"39","author":"Kolomeyer","year":"2013","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.bjps.2016.01.034_bib76","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/ICO.0b013e31823d02a8","article-title":"Indications and outcomes of amniotic membrane transplantation in the management of acute stevens-johnson syndrome and toxic epidermal necrolysis: a case-control study","volume":"31","author":"Hsu","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.bjps.2016.01.034_bib77","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2147\/OPTH.S45054","article-title":"Prompt versus delayed amniotic membrane application in a patient with acute Stevens-Johnson syndrome","volume":"7","author":"Ciralsky","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.bjps.2016.01.034_bib78","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/bjo.2007.131102","article-title":"Technique of amniotic membrane transplant dressing in the management of acute Stevens-Johnson syndrome","volume":"91","author":"Muqit","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.bjps.2016.01.034_bib79","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00002341-199803000-00013","article-title":"Standardized range of conformers and symblepharon rings","volume":"14","author":"Patel","year":"1998","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.bjps.2016.01.034_bib80","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1097\/BCR.0b013e318239f9b9","article-title":"A modified symblepharon ring for sutureless amniotic membrane patch to treat acute ocular surface burns","volume":"33","author":"Liang","year":"2012","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.bjps.2016.01.034_bib81","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.tripleo.2007.12.023","article-title":"Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention","volume":"105","author":"Sedghizadeh","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.bjps.2016.01.034_bib82","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(85)92146-4","article-title":"Sj\u00f6gren-like syndrome after drug-induced toxic epidermal necrolysis","volume":"1","author":"Roujeau","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.bjps.2016.01.034_bib83","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0030-4220(91)90300-2","article-title":"Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases","volume":"71","author":"Lozada-Nur","year":"1991","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.bjps.2016.01.034_bib84","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1600-0714.2010.00912.x","article-title":"Erythema multiforme: diagnosis, clinical manifestations and treatment in a retrospective study of 22 patients","volume":"39","author":"Sanchis","year":"2010","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.bjps.2016.01.034_bib85","first-page":"153","article-title":"Vulvovaginal sequelae in toxic epidermal necrolysis","volume":"42","author":"Meneux","year":"1997","journal-title":"J Reprod Med"},{"key":"10.1016\/j.bjps.2016.01.034_bib86","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/LGT.0b013e3181ddf5da","article-title":"Vaginal stenosis after toxic epidermal necrolysis","volume":"14","author":"Rowan","year":"2010","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.bjps.2016.01.034_bib87","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00404-009-1008-1","article-title":"Relevance and consequences of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in gynecology","volume":"280","author":"Niemeijer","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.bjps.2016.01.034_bib88","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0029-7844(97)00596-6","article-title":"Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases","volume":"91","author":"Meneux","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bjps.2016.01.034_bib89","first-page":"81","article-title":"Prevention of vulvovaginal sequelae in stevens-johnson syndrome and toxic epidermal necrolysis","volume":"4","author":"Kaser","year":"2011","journal-title":"Rev Obstet Gynecol"},{"key":"10.1016\/j.bjps.2016.01.034_bib90","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001340050492","article-title":"Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study","volume":"23","author":"Lebargy","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.bjps.2016.01.034_bib91","series-title":"(Personal communication) Dept intensive care medicine, Hopital Henri Monder","author":"De Prost","year":"2013"},{"key":"10.1016\/j.bjps.2016.01.034_bib92","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1346-8138.2006.00142.x","article-title":"Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro\/SS-A and a review of the published work","volume":"33","author":"Kamada","year":"2006","journal-title":"J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib93","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bjps.2016.01.034_bib94","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000051702","article-title":"Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience","volume":"203","author":"Stella","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.bjps.2016.01.034_bib95","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib96","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic\u00a0epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib97","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib98","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.bjps.2016.01.034_bib99","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-4632.2004.02048.x","article-title":"Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis","volume":"43","author":"Al-Mutairi","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2016.01.034_bib101","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2016.01.034_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.2005.tb00704.x","article-title":"High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series","volume":"32","author":"Tan","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib103","first-page":"119","article-title":"Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome","volume":"11","author":"Gravante","year":"2007","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.bjps.2016.01.034_bib104","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jaad.2011.12.014","article-title":"Toxic epidermal necrolysis: five years of treatment experience from a burn unit","volume":"67","author":"Firoz","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib106","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/bjd.12607","article-title":"The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre","volume":"169","author":"Lee","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib107","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.bjps.2016.01.034_bib108","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/108854100778250914","article-title":"Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases","volume":"21","author":"Tripathi","year":"2000","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.bjps.2016.01.034_bib109","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-4632.2009.04166.x","article-title":"Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China","volume":"48","author":"Yang","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib110","first-page":"743","article-title":"High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases","volume":"20","author":"Chen","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib111","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004630-199709000-00008","article-title":"Toxic epidermal necrolysis","volume":"18","author":"Murphy","year":"1997","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2016.01.034_bib112","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaad.2013.04.007","article-title":"Methylprednisolone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers","volume":"69","author":"Hirahara","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib113","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Ar\u00e9valo","year":"2000","journal-title":"J Trauma"},{"key":"10.1016\/j.bjps.2016.01.034_bib114","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib115","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4103\/0378-6323.116738","article-title":"Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid","volume":"79","author":"Singh","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.bjps.2016.01.034_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","author":"Kirchhof","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib117","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1346-8138.2010.01154.x","article-title":"Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy?","volume":"38","author":"Narita","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib118","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jca.21213","article-title":"Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases","volume":"27","author":"Ko\u0161t\u00e1l","year":"2012","journal-title":"J Clin Apher"},{"key":"10.1016\/j.bjps.2016.01.034_bib119","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib120","series-title":"Drug allergy: diagnosis and management of drug allergy in adults, children and young people","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"10.1016\/j.bjps.2016.01.034_bib121","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11588460-000000000-00000","article-title":"Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"34","author":"Butt","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.bjps.2016.01.034_bib122","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ophtha.2006.10.029","article-title":"New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome","volume":"114","author":"Sotozono","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bjps.2016.01.034_bib123","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.12925","article-title":"Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis","author":"Aihara","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib124","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/ACI.0b013e32833aa54d","article-title":"Patch testing in drug allergy","volume":"10","author":"Friedmann","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.bjps.2016.01.034_bib125","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0536.1996.tb02364.x","article-title":"Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"35","author":"Wolkenstein","year":"1996","journal-title":"Contact Dermat"},{"key":"10.1016\/j.bjps.2016.01.034_bib126","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-3083.2011.04418.x","article-title":"A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions","volume":"27","author":"Lin","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.bjps.2016.01.034_bib127","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib128","first-page":"275","article-title":"T-cell reactions to drugs in distinct clinical manifestations of drug allergy","volume":"11","author":"Neukomm","year":"2001","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.bjps.2016.01.034_bib129","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1365-2222.2001.01164.x","article-title":"T cell involvement in cutaneous drug eruptions","volume":"31","author":"Hari","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.bjps.2016.01.034_bib130","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1398-9995.2007.01553.x","article-title":"Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption","volume":"62","author":"Kano","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.bjps.2016.01.034_bib131","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2222.2011.03875.x","article-title":"Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"42","author":"Tang","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.bjps.2016.01.034_bib132","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000233856","article-title":"Lymphocyte transformation test in drug-induced toxic epidermal necrolysis","volume":"78","author":"Roujeau","year":"1985","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.bjps.2016.01.034_bib133","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2222.1997.tb00690.x","article-title":"The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity","volume":"27","author":"Nyfeler","year":"1997","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.bjps.2016.01.034_bib134","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/cea.12145","article-title":"In\u00a0vitro drug causality assessment in Stevens-Johnson syndrome \u2013 alternatives for lymphocyte transformation test","volume":"43","author":"Porebski","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.bjps.2016.01.034_bib135","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjd.12109","article-title":"In\u00a0vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions","volume":"168","author":"Polak","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2016.01.034_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-7022-4-S3-O1","article-title":"Mechanisms that limit proliferative potential of drug-specific LTT in drug-induced severe cutaneous adverse reaction patients","volume":"4","author":"Valeyrie-Allanore","year":"2014","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.bjps.2016.01.034_bib137","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2009.02180.x","article-title":"In\u00a0vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases","volume":"65","author":"Zawodniak","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.bjps.2016.01.034_bib138","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1398-9995.2008.01674.x","article-title":"Detection and quantification of drug-specific T cells in penicillin allergy","volume":"64","author":"Rozieres","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.bjps.2016.01.034_bib139","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1398-9995.2009.01985.x","article-title":"Drug-specific in\u00a0vitro release of IL-2, IL-5, IL-13 and IFN-gamma in patients with delayed-type drug hypersensitivity","volume":"64","author":"Lochmatter","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.bjps.2016.01.034_bib140","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2222.2002.01382.x","article-title":"Determination of interleukin-5 secretion from drug-specific activated ex\u00a0vivo peripheral blood mononuclear cells as a test system for the in\u00a0vitro detection of drug sensitization","volume":"32","author":"Sachs","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.bjps.2016.01.034_bib141","first-page":"865","article-title":"Multiple drug allergy in patients with cutaneous adverse drug reactions diagnosed by in\u00a0vitro drug-induced interferon-gamma release","volume":"10","author":"Halevy","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.bjps.2016.01.034_bib142","doi-asserted-by":"crossref","first-page":"e45516","DOI":"10.1371\/journal.pone.0045516","article-title":"Recovered patients with Stevens-Johson syndrome and toxic epidermal necrolysis maintain long-lived IFN-gamma and sFasL memory response","volume":"7","author":"Fu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bjps.2016.01.034_bib143","series-title":"N\u00e9crolyse \u00e9pidermique toxique (syndromes de Stevens-Johnson et de Lyell): protocole national de diagnostic et de soins","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2010"}],"container-title":["Journal of Plastic, Reconstructive & Aesthetic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1748681516000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1748681516000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T11:52:47Z","timestamp":1718625167000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1748681516000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":143,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1748681516000796"],"URL":"https:\/\/doi.org\/10.1016\/j.bjps.2016.01.034","relation":{},"ISSN":["1748-6815"],"issn-type":[{"value":"1748-6815","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UK guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in adults 2016","name":"articletitle","label":"Article Title"},{"value":"Journal of Plastic, Reconstructive & Aesthetic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.bjps.2016.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}